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Background: Radiotherapy in Hodgkin’s Lymphoma (HL) is currently evolving with new attempts to further reduce
radiation volumes to the involved-node concept (Involved Nodes Radiation Therapy, INRT) and with the use of
intensity modulated radiotherapy (IMRT). Currently, IMRT can be planned and delivered with several techniques,
and its role is not completely clear. We designed a planning study on a typical dataset drawn from clinical routine
with the aim of comparing different IMRT solutions in terms of plan quality and treatment delivery efficiency.
Methods: A total of 10 young female patients affected with early stage mediastinal HL and treated with 30 Gy
INRT after ABVD-based chemotherapy were selected from our database. Five different treatment techniques were
compared: 3D-CRT, VMAT (single arc), B-VMAT (“butterfly”, multiple arcs), Helical Tomotherapy (HT) and Tomodirect
(TD). Beam energy was 6 MV, and all IMRT planning solutions were optimized by inverse planning with specific
dose-volume constraints on OAR (breasts, lungs, thyroid gland, coronary ostia, heart). Dose-Volume Histograms
(DVHs) and Conformity Number (CN) were calculated and then compared, both for target and OAR by a statistical
analysis (Wilcoxon’s Test).
Results: PTV coverage was reached for all plans (V95% ≥ 95%); highest mean CN were obtained with HT (0.77) and
VMAT (0.76). B-VMAT showed intermediate CN mean values (0.67), while the lowest CN were obtained with TD
(0.30) and 3D-CRT techniques (0.30). A trend of inverse correlation between higher CN and larger healthy tissues
volumes receiving low radiation doses was shown for lungs and breasts. For thyroid gland and heart/coronary ostia,
HT, VMAT and B-VMAT techniques allowed a better sparing in terms of both Dmean and volumes receiving
intermediate-high doses compared to 3D-CRT and TD.
Conclusions: IMRT techniques showed superior target coverage and OAR sparing, with, as an expected
consequence, larger volumes of healthy tissues (lungs, breasts) receiving low doses. Among the different IMRT
techniques, HT and VMAT showed higher levels of conformation; B-VMAT and HT emerged as the planning
solutions able to achieve the most balanced compromise between higher conformation around the target
and smaller volumes of OAR exposed to lower doses (typical of 3D-CRT).* Correspondence: christian.fiandra@unito.it
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The overall prognosis of patients affected with early
stage Hodgkin’s lymphoma (HL) is excellent, with an
overall 15-year survival rate of more than 80%. A com-
bined modality treatment approach, consisting of a brief
chemotherapy (2 to 4 cycles of Adriamycin, Bleomycin,
Vinblastine, Dacarbazine: ABVD cycle) followed by 20–30
Gy Involved-Field Radiation Therapy (IFRT), is suggested
as the current standard of care. With most HL patients
achieving a long lasting complete remission and long-term
survival after therapy, the risk of long term complications,
particularly second malignancies, such as breast and lung
cancer [1,2] and cardiovascular disease [3,4] is of para-
mount importance.
Radiotherapy has substantially changed over the last
20 years in terms of radiation volumes and doses reduc-
tion. Two major critical points are currently under
investigation: a further shrinkage of treatment volumes
towards the involved-node(s) concept (INRT) [5] and
the employment of highly conformal techniques such as
Intensity-Modulated Radiation Therapy (IMRT). INRT
can theoretically reduce radiation-induced late effects by
reducing treatment volumes, while IMRT has the poten-
tial to substantially improve dose distribution, reducing
the amount of healthy tissues exposed to intermediate-
high dose level. Such a dosimetric gain could be particu-
larly important in mediastinal disease [6], for which
there is growing evidence that highly conformal irradi-
ation modalities may improve critical organs sparing
with clinically significant consequences.
We herein report on a comparative planning study of
INRT actually delivered with 3D-CRT and different
known IMRT solutions (HT and VMAT) in a cohort of
young female patients affected with early stage HL and
mediastinal involvement. The present study also intro-
duces TomoDirect™ as a rapid, low-modulation solution
of the Tomotherapy HI-ART II platform, and a specific
volumetric IMRT approach designed in our Institution
for lymphoma patients and named Butterfly-VMAT
(B-VMAT, so called for typical butterfly-shaped low
isodoses), based on multiple arcs (two coplanar arcs and
one non-coplanar arc). The primary aim of the study was
to investigate the most appropriate planning solution, in
terms of plan quality (target coverage and OAR sparing)
and treatment efficiency.
Methods
Ten consecutive female patients affected with early stage
HL with mediastinal involvement, submitted to radio-
therapy from April 2008 to September 2009 at our Insti-
tutions, were enrolled onto the present study. Median
age was 26.5 years old. All patients received standard
combined modality treatment with 3 or 4 cycles of ABVD
chemotherapy (respectively favourable or unfavourableearly stages according to EORTC prognostic risk factors),
followed by Involved Nodal Radiotherapy (INRT) at a
dose of 30 Gy/15 fractions (according to EORTC H10
protocol radiotherapy guidelines). Two out of 10 patients
had mediastinal bulky disease at presentation, 2/10
hilar involvement, 4/10 supraclavicular involvement, 6/10
supraclavicular and upper neck involvement. None of
the patients had extranodal disease. Patients with axillary
involvement were excluded.
All patients had pre and post-chemotherapy contrast-
enhanced Computed Tomography (CT) and FDG-PET
Computed Tomography (FDG-PET-CT) scans. All patients
were contoured on Oncentra Masterplan TPS station Ver-
sion 4.1 (Nucletron, Veenendal, The Netherlands). CT simu-
lation scans were all non contrast-enhanced, with a slice
thickness of 3 mm; images were acquired in treatment po-
sition, using immobilization devices usually consisting of
thermoplastic masks.
Clinical Target Volume (CTV) and Organs-at-Risk
(OAR) were contoured by the same 2 radiation oncologists.
INRT CTV was defined according to EORTC-GELA
guidelines [1], as the pre-chemotherapy CTV (contoured
on the basis of pre-chemotherapy CT and PET-CT
scans) modified according to post-chemotherapy ana-
tomic boundaries. As recommended by EORTC-GELA
guidelines, major blood vessels and heart were excluded
whenever possible. A 8 mm isotropic margin was added
to CTV to generate Planning Target Volume (5 mm to
compensate for target motion of mediastinal lymph
nodes and 3 mm for set-up error, with a daily cone-
beam CT IGRT protocol).
Lungs, thyroid, breasts, heart and coronary ostia were
defined as organs at risk (OAR) and delineated on CT
datasets; for the breast glandular tissue we used a stand-
ard window (0) and width (500) level. The heart was
defined from the auricles to the tip of the organ, includ-
ing thus all cardiac chambers. The origin of the coronary
arteries was defined as the outer circumference of the
proximal aorta, extending from the tip of the auricles to
the bulb of the aorta (usually 2.5-3 cm, with slight indi-
vidual differences). Non-target tissue was defined as
the patient’s volume covered by the CT scan (external
patient contour) minus the PTV.
Prescription dose was 30 Gy in 2 Gy daily fractions as
mean PTV dose for all plans. As goal for dose homo-
geneity we intentionally decided not to follow recom-
mendation of ICRU No. 83 in terms of dose coverage.
The classical objectives defined by ICRU No. 50 (in
which the target must be covered by more than 95% and
less than 107% of the prescription dose), have been con-
sidered more appropriate in this setting (volumes close
to skin surface, high radiosensivity, microscopic disease).
The maximum tolerated dose was 115% of the pre-
scribed dose (i.e., 34.5 Gy) in one voxel for the case of
Figure 1 3D-graphical representation of the arc /beams
configuration employed in Butterfly VMAT (B-VMAT) approach.
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modalities. Dose objectives for OAR (Table 1) were
derived from a previously published study with the aim
of a potential comparison [7]. Beam energy for all plans
was 6 MV. All ten patients were actually treated with
3D-CRT and all treatments were then re-planned; there-
fore, five radiotherapy treatment plans were generated
for each patient: 3D-conformal (3D-CRT) plan, single-
arc VMAT plan (VMAT), three arcs VMAT plan (named
“butterfly” VMAT, or B-VMAT), Helical Tomotherapy
plan (HT) and TomoDirect™plan (TD).
Conventional 3D-CRT plans consisted of 2 anterior-
posterior parallel opposed fields (gantry angles 0°-180°),
shaped with multi-leaf collimators on beam’s-eye-view.
Calculations were performed with Oncentra Masterplan
using Collapsed Cone algorithm.
The two VMAT plans consisted either of a single
arc of 360° (gantry starting angle 180°) or a 3 arcs plan
(B-VMAT), developed and chosen in our Institution as
preferred class solution in lymphoma patients with
mediastinal involvement in order to reduce low doses
radiation exposure (“bath doses”) to lungs and breasts;
this approach consists of 2 coplanar arcs of 60° (gantry
starting angles 150° and 330°) and 1 no-coplanar arc
of 60° (gantry starting angles 330°, couch angle 90°)
(Figure 1).
VMAT plans (both single-arc VMAT and B-VMAT)
were computed on Elekta Monaco treatment planning
system (TPS version 3.0). Monaco TPS allows a peculiar
dose optimization by biological cost-functions for both
PTV and OARs, using 3 main functions: the Poisson sta-
tistics cell-kill model, the serial complication model
and the parallel complication model. Three-dimensional
dose distributions are converted to either a EUD for the
Poisson cell kill model and Serial complication model orTable 1 Dose objectives for traditional dose optimization






Breast V4Gy (%) 50
V10Gy (%) 33
Lung V5Gy (%) 50
V10Gy (%) 33
Thyroid V18Gy (%) 50
V25Gy (%) 33
Heart V7.7Gy (%) 50
V15Gy (%) 33
Coronary Ostia V20Gy (%) 100a fraction of organ damaged for the parallel complication
model [8]. These biological parameters are then included
in the overall objective score for plan optimization. Each
parameter is changed during optimization process to
minimize the objective function describing coverage of
PTV and sparing of each OAR. All VMAT plans were
planned for Elekta Axesse™ Linear Accelerator, with its
specific Beam Modulator (with 4 mm leaf width at iso-
center) employed to achieve the desired beam’s fluence.
The XVMC/VEF Monte Carlo algorithm with a 3% vari-
ance was used for all cases [9]. Calculation grid was set
to 3 mm.
HT and TD plans were created and optimized using
TomoTherapy Hi-Art version 4.0.5 TPS (Accuray, Inc.,
Sunnyvale, CA). For each plan, the treatment field width,
pitch (the TD pitch is defined as the distance of couch
travel in centimetres per sinogram projection) and modu-
lation factor need to be selected. Then, the dose distri-
bution for each beamlet that passes through the target
is calculated by a convolution/superposition algorithm.
Once the beamlet calculation step is completed, the
optimization process begins and an iterative least-squares
minimization method is used to optimize the objective
function. During the final dose computation the opti-
mized sinogram is converted to the delivery sinogram,
taking into account for leaf fluence output factors and
latency data. A fine calculation grid (256x256 pixels) was
used both in the optimization and calculation processes.
HT treatments were planned with a modulation factor
between 2.6 and 3.7, a pitch of 0.287 and a field width of
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between cranio-caudal dose spread (lower than a 50 mm
field width) and treatment time (lower than a 10 mm
field width).
In TD plans, only a two opposed beam configuration
was investigated because it better reproduces the stand-
ard 3D-CRT technique. A planning modulation factor
between 2.0 and 2.2 and a jaw width of 25 mm were
used. The pitch value was set to the default value that is
one tenth of the field width (2.5 mm/projection for the
25 mm beam).
Quantitative evaluation was performed by means of
cumulative dose-volume histograms (DVHs). Analyzed
parameters for PTV included Dmean, V95, V107, Conform-
ation Number (CN) and Homogeneity Index (HI). Plan
conformity was evaluated using the CN proposed by
van’t Riet et al. [10] which takes into account the overlap
of the prescription isodose line with the PTV as well as
the dose spilling over normal tissue. CN is defined as
CN = TV2PI/ TV
x VPI where VPI is the volume of the pre-
scription isodose, TV is the planning target volume, and
TVPI is the planning target volume covered by the pre-
scription isodose. The maximum CN value is 1 as it is
achieved for an ideal plan [11]. Homogeneity index was
defined by the equation HI =(D2-D98)/Dp where D2 and
D98 are respectively doses received by 2% and 98% of
volume while Dp is the prescription isodose.
Analyzed parameters for OAR were mean dose and
representative Vd. For each plan the delivery treatment
time was estimated. The Wilcoxon matched-paired
signed-rank test was used to compare the results among
all different 5 techniques. The threshold for statistical sig-
nificance was p≤0.05. All statistical tests were two-sided
and were performed using the Systat version 7.0.1 (Systat
Software, Inc.225 Chicago, USA).V4, V5 and V20 for lungs
and breasts were plotted with CN by scatterplot.
Results
Figure 2 represents the dose distributions in a single
patient with all different five techniques while detailed
results of the planning comparison for the 5 different
techniques in all 10 patients (mean values) are shown
in Table 2.
PTV
All dose and volumes data were calculated as mean
values of the 10 considered patients. Mean doses to the
PTV were almost identical. Dmean varied from a mini-
mum value of 29.9 Gy for HT to a maximum value of
30.6 Gy for 3D-CRT. The best target coverage according
to ICRU 50 definitions was obtained with HT and TD
(V90% = 99.1 and 99.2, respectively), even if the target
coverage was optimal also for 3D-CRT, VMAT and
B-VMAT, as shown in Table 2. 3D-CRT, B-VMAT andVMAT techniques had higher values of V107% (5%, 5.5%
and 4.3%). Conformation Number reached a maximum
value of 0.77 with HT, followed by VMAT with 0.76;
B-VMAT had an intermediate value of 0.67, while TD
achieved CN value of 0.3 like 3D-CRT. Homogeneity
Index values of HT (HI = 0.07) and TD (HI = 0.1) were
lower than all other techniques.
Lungs
Dmean showed similar values for all different techniques,
including 3D-CRT. For low doses (V5), a trend of
increased volumes may be observed from 3D-CRT (mean
value of 29.3%) to VMAT (mean values of 39.0%). For
volumes receiving higher doses (V20), the maximum value
was reached by TD (V20 = 15.6 %), with lowest values for
IMRT techniques with the highest CN. Figure 3 shows
the correlation between CN values and V5 - V20values: a
trend for a correlation with CN is appreciable.
Breasts
Dmean showed comparable values between HT and
VMAT (1.2 ± 0.9 and 0.9 ± 0.4), but significant differ-
ence in terms of reduced mean dose of B-VMAT
(p<0.05) compared with all others techniques may be
observed (Table 2).
V4 values for 3D-CRT and TD were respectively 4.5%
and 3.7%, while for VMAT and HT V4 values were re-
spectively 6.2% and 5.4%. For B-VMAT, the V4 value was
similar to 3D-CRT (4.6%). V15 and V20were low for all
different techniques (range 0.3-1.6 for V15 and 0.1-1.3
for V20). Figure 3 shows the correlation between CN
values and V4 and V20; a trend for an inverse correlation
is appreciable only for V4.
Thyroid gland
Dmean for thyroid gland were lower for HT, VMAT and
B-VMAT (14.4, 13.5 and 13.5 Gy) compared to TD and
3D-CRT (17.3 and 17.7 Gy). From the analysis of the
values of each single patient (not reported in the manu-
script), come out as only techniques able to achieve
higher CN values (more than 0.6) are ever able to satisfy
the dose objectives indicated for thyroid.
Coronary Ostia
Mean dose as well as V20 values were comparable for all
techniques; treatment plans with higher CN values did
not translate into a substantial sparing of this organ at
risk, as in most of cases coronary ostia were distant from
target volumes.
Heart
Mean Dose received by the whole heart was similar
(range 3.1 – 5.1 Gy) for all different techniques.
Figure 2 Dose distributions achievable in patient number 4 with all different five techniques.
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No significative differences were found in terms of Dmean
to the whole considered body; however the minimum
value was reached by B-VMAT technique (3.1 Gy) while
3D-CRT had the maximum mean value of 4.1 Gy.Treatment efficiency
All techniques had clinically acceptable treatment
times. IMRT techniques showed higher treatment times
(a mean values of 7.2 minutes for HT, 6.2 minutes
for VMAT (single arc) and 12 minutes for B-VMAT),
while 3D-CRT and TD were significantly faster (3.2 and
4.4 minutes).Conformation number
Each planning method gives different values of CN
based on its degree of modulation. Figures 3a and 3b
show the trend of “low” doses (V4,V5) and “high” doses
(V20) as a function of CN for all different techniques,
respectively for lungs (Figure 3a) and breast (Figure 3b).
For lungs, volumes receiving low doses (V5) started from
20% for lower CN techniques (corresponding to 3D-
CRT and TD) to 50% values for higher CN techniques.
An opposite trend is shown for volumes receiving “high”
doses (V20), shifting from 15% for lower CN approaches
to roughly 5% for higher CN techniques (HT and
VMAT). For breast tissues, a same trend was evident forvolumes receiving low doses (V4), but not for volumes
receiving higher doses (V20).Discussion
There is growing evidence that highly conformal irradi-
ation modalities, like different IMRT approaches, may
improve critical organs sparing by improving conformity
[6,7,12-15], with potentially clinical significant conse-
quences in haematological malignancies.
The open question is whether IMRT might lead to a
lower dose to the surrounding organs and whether the
rate of late complications (in particular lung and cardiac
toxicity) could be really reduced with IMRT.
In this comparative planning study, we evaluated dif-
ferent photons IMRT solutions applying the INRT con-
cept, in comparison with the actual reference technique
3D-CRT.
Helical Tomotherapy and VMAT were tested as very
highly conformal techniques for PTV coverage, with also
the potential advantage of a faster delivery solution for
VMAT (one rotation only). B-VMAT was specifically
developed in our Institution for HL patients with medi-
astinal involvement, in order to achieve a highly con-
formal solution lowering radiation exposure of lungs and
breasts. TD represented a feasible and simple alternative
planning solution for Tomotherapy if a low degree of
modulation is desired.
Table 2 Comparison of mean dosimetric parameters computed for 3D-CRT, TD, B-VMAT, VMAT and HT
Variable Objectives 3D-CRT TD B-VMAT VMAT HT
PTV
Volume (cm3) 428.7 ± 195.6
DMean 30 30.6±0.7
b,e 30.0±0.1a,c,d 30.4±0.2b,e 30.4±0.2b,e 29.9±0.1a,c,d
V90% (%) 99 98.2±1.0
b,d,e 99.2±0.7a,c,d 98.3±1.2b,e 98.6±1.1b,e 99.1±0.2a,c,d
V95% (%) 95 94.8±0.5
b,d,e 97.4±1.7a,c,d,e 95.5±2.3b 95.4±1.7b 95.9±0.7a,b
V107% (%) <1 5.0±5.2
b,d,e 0.02±0.03a,c,d,e 5.5±3.8b,e 5.50±3.80b,e 0.3±0.28a,b,c,d
CN95% (%) 1 0.30±0.1
c,d,e 0.30±0.1c,d,e 0.67±0.1a,b,d,e 0.76±0.02a,b,c 0.77±0.06a,b,c
HI 0 0.30±0.1b,c,d,e 0.10±0.03a,c,d,e 0.20±0.1a,b,e 0.16±0.04a,b,e 0.07±0.01a,b,c,d
Lung
Dmean(Gy) - 6.6±2.6 6.3±2.7 5.9±2.5 6.4±2.5 5.9±2.2
V5Gy (%) 50 29.3±12.4
b,c,d,e 26.4±11.6a,c,d,e 31.3±14.3a,b,d,e 39.0±15.6a,b,c 37.0±12.6a,b,c
V10Gy (%) 33 22.6±9.4
d 21.9±9.6d 20.8±10.0d 25.6±13.3a,b,c,e 20.6±11.0d
V15Gy (%) - 18.6±7.6
c,d,e 18.5±8.2c,d,e 15.3±8.0a,b,e 15.0±10.6a,b,e 12.8±7.5a,b,c,d
V20Gy (%) - 15.2±6.2
c,d,e 15.6±6.9c,d,e 11.3±6.7a,b,d,e 8.8±6.3a,b,c, 7.6±4.5a,b,c
V30Gy (%) - 3.5±2.7
b,c,d,e 0.7±0.5a 0.8±0.8a 0.3±0.3a 0.1±0.3a
Breast
Dmean(Gy) - 1.0±0.4
c 0.9±0.9c 0.7±0.3a,b,d,e 0.9±0.4c 1.2±0.9 c
V4Gy (%) 50 4.5±2.3
d,e 3.7±4.2d,e 4.6±3.0d,e 6.2 ±4.7a,b,c 5.4±5.5a,b,c
V10Gy (%) 33 2.5±1.4
c,d,e 2.4±3.0c,d,e 1.1±1.0a,b 1.2±1.1a,b 1.4±1.8a,b
V15Gy (%) - 1.4±0.7
c,d,e 1.6±2.2c,d,e 0.4±0.4a,b 0.3±0.4a,b 0.6±1.0a,b
V20Gy (%) - 0.9±0.5
c,d 1.3±1.9c,d 0.1±0.1a,b 0.1±0.1a,b 0.2±0.5a,b
V30Gy (%) - 0.2±0.3
c,d,e 0.6±1.0c,d,e 0a,b 0a,b 0a,b
Thyroid
Dmean(Gy) - 17.7±4.5
c,d,e 17.3±5.1c,d,e 13.5±6.3a,b 13.5±5.3a,b 14.4±5.5a,b
V18Gy (%) 50 45.9±18.1
c,d,e 51.3±19.2c,d,e 35.2±21.6a,b 33.4±18.8a,b 38.2±23.0a,b
V25Gy (%) 33 32.0±14.4
c,d,e 32.9±14.6c,d,e 22.2±15.8a,b 21.3±14.7a,b 24.5±19.8a,b
Coronary Ostia
Dmean(Gy) - 22.1±9.9
c,d,e 19.8±9.3c,d,e 15.7±7.9a,b 15.9±8.9a,b 16.4±8.4a,b
V20Gy (%) 100 73.5±40.8
c,d,e 59.1±37.7c,d,e 43.1±32.6a,b 44.0±34.3a,b 44.3±34.2a,b
Heart
Dmean(Gy) - 5.1±4.0
c,d,e 4.3±3.7c,d,e 3.5±2.3a,b 3.1±2.2a,b 3.8±3.8a,b
Non target tissue
Dmean(Gy) - 4.1±1.3 3.8±0.9 3.1±0.7 3.6±0.9 3.90±0.96
Time (min) - 3.2±1.1b,c,d,e 4.4±1.1a,c,d,e 12.0±2.8a,b,d,e 6.2±1.3a,b,c,e 7.2±1.6a,b,c,d
Statistically significant differences (p<0.05) for each technique versus alternatives are reported: aTest vs 3D-CRT; b Test vs TD; c Test vs B-VMAT; d Test vs VMAT;
e Test vs HT.
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form the dose to PTV compared to 3D-CRT, even if the
standard 3D-CRT approach lead to a valid target cover-
age, satisfying ICRU criteria (V95%> 95%); better PTV
coverage achieved by IMRT is depending of course on
the IMRT ability, regardless of different technical
approaches, to modulate the intensity of each radiation
beam, resulting on a higher conformal delivery of radi-
ation dose to PTV. Among different IMRT techniques,
HT and VMAT showed the best level of conformity to
PTV (Table 2, p<0.05 for CN); VMAT and B-VMAT had
higher values of the maximum dose (V107%), howeverbetter results in terms of homogeneity of dose inside
PTV are promised for future version of Monaco soft-
ware. All different IMRT solutions were also better in
terms of lowering mean doses to certain OAR (thyroid
gland, heart and coronary ostia,), as already shown by
other Authors in similar planning comparison studies
[7,12,13]. For such organs, in which probably a lower
mean dose is potentially correlated to a lower incidence
of late toxicity, IMRT confirms its advantage in our
series, with all different modulated techniques able to
better spare thyroid gland; it is reasonable that lowering
the radiation dose to the thyroid gland could reduce
Figure 3 Lung and breast volumes (%) receiving 4–5 Gy and 20 Gy plotted as a function of CN for all available different techniques.
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cancer [16].
A substantial avoidance of heart and coronary ostia
has been however achieved independently from IMRT,
by simply applying the INRT concept other than the
wider IFRT approach (in 8 out of our 10 patients, these
structures received very low doses), as previously shown
by Koeck et al. [17], reporting no significant difference
in cardiac Dmean between 3D-CRT and IMRT when
using INRT. Some authors stated that the aim of heart
sparing could be best achieved with IMRT [18]. Anyway,
the individual magnitude of clinical benefit related to a
possible IMRT dosimetric gain is hard to predict, mainly
depending on adjunctive risk factors (patient anatomy,
entity of mediastinal involvement, cardiac comorbidity).
In the near future, at least in critical anatomical presen-
tations and in clinical cases at risk for cardiac toxicity,
new different approaches, such as proton therapy, could
probably further reduce cardiac radiation doses (a strong
reduction of heart exposure as well as of radiation
doses to critical cardiac subunits was reported by Hoppe
et al. [19]).
One of the aims of IMRT in supradiaphragmatic HL
patients is to reduce radiation exposure to lungs; Dmean
to lungs was similar for all different technical
approaches, including 3D-CRT; all IMRT techniques
were able to significantly reduce volumes receiving high
doses (>20 Gy); this could be expected to translate
into a lower incidence of acute radiation pneumonitis
(Girinsky et al. [12] reported a grade >2 lung toxicity
in 10% of the cases with mean dose of 12.8 Gy and in
5% with average V20 of 25% in treating HL patients with
mediastinal masses). Opposite to a reduction of V20
values, IMRT techniques resulted in an increase of V5
parameter. For low doses pulmonary volumes (V5),
higher was the CN of each different technique, higher
were the corresponding V5 values; on the other hand,
there was an inverse correlation between CN and lungs
V20 (as the CN decreases, higher V20 values areobtained). The slope of the correlation curves shown in
Figure 3 suggests that the CN achievable with different
techniques could be considered as a potential endpoint
(the best compromise between low and high doses
volumes) for planning.
The impact of low dose radiation exposure to large
breasts’ volume on the risk of developing a secondary
cancer is currently unknown; there are some clear data
showing a risk reduction with lower doses and smaller
volumes [20], but there are still uncertainties on which
dose distribution to the breasts is the most conservative
[21]. Comparing Dmean between 3D-CRT and IMRT we
find comparable results; in our experience the B-VMAT
solution, specifically designed as our class solution for
lymphoma patients involving the mediastinum, seems
to be the most appropriate, obtaining Dmean values of
0.7 Gy (little bit lower than those achieved with other
planning solutions, p<0.05). Dmean values obtained in
our study with all different techniques are in any case
comparable to those reported in other experiences [21],
even if with a broad range of V4 and CN values, strongly
dependent on patients’ specific anatomy (Figure 3).
The dose to non-target tissue did not significantly vary
among all different techniques (slightly higher for tech-
niques with higher CN values).
Although some experience are reported in literature
[22] about the comparison of treatment plans resulting
from optimization methods based on physical dose or
biological parameters, the present study is the first
experience evaluating volumetric IMRT techniques based
on radiobiological planning in treating HL patients,
as well as the first experience comparing them with
Tomotherapy-based solution (classical HT); radiobio-
logical optimization, specifically part of the Monaco
IMRT planning process, was able to respect all dose con-
straints and to obtain satisfactory dose distribution, both
for PTV coverage and OAR’s sparing. A planning option
that has not been investigated in the present study, but
that can achieve similar dose distribution, is traditional
Fiandra et al. Radiation Oncology 2012, 7:186 Page 8 of 9
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by other groups with the use of 9 static coplanar IMRT
fields [7].
IMRT reduces high doses to OAR to a varying degree,
depending on prescription strategies and target para-
digm, at the cost of larger volumes irradiated to low/
intermediate doses, whose clinical significance is now-
adays unknown. Considering all different OAR’s toge-
ther, we were not able to find out an optimal IMRT
technique, with constantly better dosimetric perfor-
mances; one of the reasons could stand in the anatom-
ical differences between 10 included patients, as well as
in the INRT approach itself, able to achieve a good spar-
ing of most OAR even with less conformal techniques
[23]. In this setting, IMRT represents a continuum of
possible dose distributions, being the choice of the
specific technique apparently of minor importance. In
our clinical routine the decision to use IMRT or not is
made on an individual basis after comparative treatment
planning, with the largest benefit to be expected in
patients with large mediastinal targets.
A future generation of studies would probably con-
sider different IMRT solutions for different disease pre-
sentations at diagnosis, including second cancer risk
modeling in the planning process.Conclusions
IMRT techniques showed superior target coverage and
OAR sparing compared to 3D-CRT, with, as expected,
larger volumes of some healthy tissues (especially lungs
and breasts) receiving low-intermediate doses.
Among different IMRT techniques, HT and VMAT
showed the highest levels of conformity; TD performances
were, as expected, very similar to those of 3D-CRT;
B-VMAT and HT emerged as the planning solutions able
to obtain the most appropriate compromise and balance
between conformity around the target (typical of IMRT)
and limited volumes of OAR receiving low-intermediate
radiation doses (typical of 3D-CRT).
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